Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review

Two phase 3 trials reported a prolonged survival in the third‐line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunetti, Oronzo, Calabrese, Angela, Palermo, Loredana, Solimando, Antonio Giovanni, Argentiero, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935656/
https://www.ncbi.nlm.nih.gov/pubmed/31893063
http://dx.doi.org/10.1002/ccr3.2496
Descripción
Sumario:Two phase 3 trials reported a prolonged survival in the third‐line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.

Ejemplares similares